预约演示
Pfizer finds room for ADC snack after swallowing Seagen, inking deal for mesothelin candidate
引进/卖出抗体药物偶联物临床申请
Pfizer has identified the candidate as an asset that can realize the potential of mesothelin as an ADC target.
Pfizer just swallowed a $43 billion antibody-drug conjugate (ADC) company and stilmesothelinll. Hours after Pfizer closed the Seagen buyout, Nona Biosciences put out news that the Big Pharma has committed $53 million in upfront and near-term payments for rights to its mesothelin-targeted ADC.
Pfizeral with Nona gives Pfizer an exclusive global license tADChe ADC, dubbed HBM9033, a drug candidate thaPfizerived FDA cleSeagen for testNona Biosciencesrlier this year. Harbor BioMed, Nona’s parent company, created the asset in collaboration with MediLink Therapeumesothelining technoADCies to link an anti-mesothelin antibody to a novel topoisomerase inhibitor via a tumor-specific cleavable linker.
Pfizer, which Nonan the hPfizerr up to $1.05 billion in milestones,ADCs identifHBM9033 candidate as an asset that can realize the potential of mesothelin as an ADC target. A mesothelin ADC Nonaidate that Bayer developed with ImmunoGen and MorphoSys faiMediLink Therapeuticsn mesothelioma patients in 2017.tumor
Pfizerremained interested in the target, inking and then axing a CAR-T pact with Atara Biotherapeutics, and other companies have kept in the humesothelina range of modalitiesmesothelin ADC reflects evidenBayerat mesothelin isImmunoGenessedMorphoSysple tumor types, including mesothelioma and cancers of the ovary, lung, breast and pancreas.
Bayereal further strengthens Pfizer’s position in a modality that CEO Albert BourAtara Biotherapeutics hottest” areas of business development in recent months on a call with investors to discuss the closure of thmesothelineal. “Everybody is looking fortumorDC and actually thmesotheliomat we'cancers being paid for ADCs are way, way higher than what we were able to get [Seagen for],” Bourla said.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。